HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy

Detalhes bibliográficos
Autor(a) principal: Saraiva, Diana P.
Data de Publicação: 2018
Outros Autores: Jacinto, António, Borralho, Paula, Braga, Sofia, Cabral, M. Guadalupe
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.3389/fimmu.2018.02605
Resumo: This work was supported by iNOVA4Health - UID/Multi/04462/2013 - LISBOA-01-0145-FEDER-007344, Fundacao para a Ciencia e Tecnologia - PD/BD/114023/2015 and PTDC/BBB-BMD/4497/2014. Liga Portuguesa Contra o Cancro.
id RCAP_254c9f7f3dc094b52f0d8e57adba6bec
oai_identifier_str oai:run.unl.pt:10362/54695
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapyBreast cancerCytotoxic T lymphocytesHLA-DRNeoadjuvant chemotherapyPredictionImmunology and AllergyImmunologySDG 3 - Good Health and Well-beingThis work was supported by iNOVA4Health - UID/Multi/04462/2013 - LISBOA-01-0145-FEDER-007344, Fundacao para a Ciencia e Tecnologia - PD/BD/114023/2015 and PTDC/BBB-BMD/4497/2014. Liga Portuguesa Contra o Cancro.Prediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent need to promptly direct non-responder patients to alternative therapies. Infiltrating T lymphocytes, namely cytotoxic T lymphocytes (CTLs) have been appointed as predictors of response. However, cancer cells have the ability to dampen CTLs' activity and thus, the prognostic value of the CTLs, per se, is debatable. Here, we disclose that more than the occurrence of CTLs, it is their activation state, revealed by HLA-DR expression, that can accurately predict response to NACT. Flow cytometry analysis of breast cancer biopsies showed that the frequency of CTLs and other lymphocytes were similar regardless disease stage and between NACT responders and non-responders. However, only breast cancer patients without axillary lymph node metastasis and NACT responders have HLA-DRhi CTLs. Interestingly, HLA-DR levels in tumor CTLs is correlated with HLA-DR levels in systemic CTLs. These HLA-DR+ CTLs produce IFN-? And Granzyme B, enlightening their effector and probable anti-tumor activity profile. Moreover, the level of HLA-DR in CTLs is negatively correlated with the level of HLA-DR in T regulatory lymphocytes and with immunosuppressive and pro-tumor molecules in the tumor microenvironment. Hence, HLA-DR levels in CTLs is a highly sensitive and specific potential predictive factor of NACT-response, which can be assessed in blood to guide therapeutic decisions.Centro de Estudos de Doenças Crónicas (CEDOC)NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNSaraiva, Diana P.Jacinto, AntónioBorralho, PaulaBraga, SofiaCabral, M. Guadalupe2018-12-14T23:18:33Z2018-11-132018-11-13T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.3389/fimmu.2018.02605eng1664-3224PURE: 7054405http://www.scopus.com/inward/record.url?scp=85056623342&partnerID=8YFLogxKhttps://doi.org/10.3389/fimmu.2018.02605info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:36:05Zoai:run.unl.pt:10362/54695Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:36:05Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
title HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
spellingShingle HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
Saraiva, Diana P.
Breast cancer
Cytotoxic T lymphocytes
HLA-DR
Neoadjuvant chemotherapy
Prediction
Immunology and Allergy
Immunology
SDG 3 - Good Health and Well-being
title_short HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
title_full HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
title_fullStr HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
title_full_unstemmed HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
title_sort HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy
author Saraiva, Diana P.
author_facet Saraiva, Diana P.
Jacinto, António
Borralho, Paula
Braga, Sofia
Cabral, M. Guadalupe
author_role author
author2 Jacinto, António
Borralho, Paula
Braga, Sofia
Cabral, M. Guadalupe
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Centro de Estudos de Doenças Crónicas (CEDOC)
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Saraiva, Diana P.
Jacinto, António
Borralho, Paula
Braga, Sofia
Cabral, M. Guadalupe
dc.subject.por.fl_str_mv Breast cancer
Cytotoxic T lymphocytes
HLA-DR
Neoadjuvant chemotherapy
Prediction
Immunology and Allergy
Immunology
SDG 3 - Good Health and Well-being
topic Breast cancer
Cytotoxic T lymphocytes
HLA-DR
Neoadjuvant chemotherapy
Prediction
Immunology and Allergy
Immunology
SDG 3 - Good Health and Well-being
description This work was supported by iNOVA4Health - UID/Multi/04462/2013 - LISBOA-01-0145-FEDER-007344, Fundacao para a Ciencia e Tecnologia - PD/BD/114023/2015 and PTDC/BBB-BMD/4497/2014. Liga Portuguesa Contra o Cancro.
publishDate 2018
dc.date.none.fl_str_mv 2018-12-14T23:18:33Z
2018-11-13
2018-11-13T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.3389/fimmu.2018.02605
url https://doi.org/10.3389/fimmu.2018.02605
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1664-3224
PURE: 7054405
http://www.scopus.com/inward/record.url?scp=85056623342&partnerID=8YFLogxK
https://doi.org/10.3389/fimmu.2018.02605
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545666055897088

Registros relacionados